Publicaciones

Mantzaris I, Goldfinger M, Uriel M, Shastri A, Shah N, Gritsman K, Kornblum N, Shapiro LC, Sica A, Munoz A, Chambers N, Dhawan A, Verceles JA, Fehn K, Tirone B, Shah L, Clark S, Zhang C, Kim MY, Cooper DL, Verma A, Konopleva MY, Feldman EJ. Venetoclax plus Daunorubicin and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia: Results of a Phase 1b Study. Blood. 2025 Feb 7:blood.2024026700. doi: 10.1182/blood.2024026700. Epub ahead of print. PMID: 39919267

Chakraborty S, Morganti C, Pena BR, Zhang H, Verma D, Zaldana K, Gitego N, Ma F, Aluri S, Pradhan K, Gordon S, Mantzaris I, Goldfinger M, Feldman E, Gritsman K, Shi Y, Hubner S, Qiu YH, Brown BD, Skwarska A, Verma A, Konopleva M, Tabe Y, Gavathiotis E, Colla S, Gollob J, Dey J, Kornblau SM, Koralov SB, Ito K, Shastri A. A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid Leukemia. bioRxiv [Preprint]. 2024 Aug 7:2024.08.05.599788. doi: 10.1101/2024.08.05.599788. PMID: 39211137; PMCID: PMC11361003

Ben-Crentsil NA, Mohammed Ismail W, Balasis ME, Newman H, Quintana A, Binder M, Kruer T, Neupane S, Ferrall-Fairbanks MC, Fernandez J, Lasho TL, Finke CM, Ibrahim ML, McGraw KL, Wysota M, Aldrich AL, Ryder CB, Letson CT, Traina J, McLemore AF, Droin N, Shastri A, Yun S, Solary E, Sallman DA, Beg AA, Ma L, Gaspar-Maia A, Patnaik MM, Padron E. RNA shielding of P65 is required to potentiate oncogenic inflammation in TET2 mutated clonal hematopoiesis. Cancer Discov. 2024 Aug 27. doi: 10.1158/2159-8290.CD-24-0093. Epub ahead of print. PMID: 39189614

Aminov S, Giricz O, Melnekoff DT, Sica RA, Polishchuk V, Papazoglu C, Yates B, Wang HW, Sahu S, Wang Y, Gordon-Mitchell S, Leshchenko VV, Schinke C, Pradhan K, Aluri S, Sohn M, Barta SK, Agarwal B, Goldfinger M, Mantzaris I, Shastri A, Matsui W, Steidl U, Brody JD, Shah NN, Parekh S, Verma A. Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency. J Clin Invest. 2024 Feb 20:e175199. doi: 10.1172/JCI175199. Epub ahead of print. PMID: 38376944.

Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Patel PA, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern AE, O'Connell CL, Roboz GJ, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Shastri A, Dao KH, Oganesian A, Hao Y, Keer HN, Azab M, Savona MR. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024 Jan;11(1):e15-e26. doi: 10.1016/S2352-3026(23)00338-1. PMID: 38135371.

Wei JX, Shastri A, Sica RA, Mantzaris I, Kornblum N, Shah U, Janakiram M, Gritsman K, Verma A, Goldfinger M, Cooper D, Shah N. Impact of race and ethnicity on early mortality in multiple myeloma: a SEER analysis. Haematologica. 2023 Oct 26. doi: 10.3324/haematol.2023.283304. Epub ahead of print. PMID: 37881838.

Vegivinti CTR, Keesari PR, Veeraballi S, Martins Maia CMP, Mehta AK, Lavu RR, Thakur RK, Tella SH, Patel R, Kakumani VK, Pulakurthi YS, Aluri S, Aggarwal RK, Ramachandra N, Zhao R, Sahu S, Shastri A, Verma A. Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review. Exp Hematol Oncol. 2023 Jul 8;12(1):60. doi: 10.1186/s40164-023-00422-1. PMID: 37422676; PMCID: PMC10329313.

Chai J, Choudhuri J, Wang Q, Fang Y, Shi Y, Kamel J, Shah N, Sica RA, Kornblum N, Konopleva M, Mantzaris I, Shastri A, Gritsman K, Verma A, Goldfinger M, Goel S, Wang Y, Tian X. Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation. Leuk Lymphoma. 2023 Jul 10:1-11. doi: 10.1080/10428194.2023.2232494. Epub ahead of print. PMID: 37424335.

Levitz D, Saunthararajah Y, Fedorov K, Shapiro LC, Mantzaris I, Shastri A, Kornblum N, Sica RA, Shah N, Konopleva M, Gritsman K, Braunschweig I, Cooper DL, Pradhan K, Verma A, Feldman EJ, Goldfinger M. A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML. Clin Cancer Res. 2023 Jun 21:OF1-OF7. doi: 10.1158/1078-0432.CCR-23-0842. Epub ahead of print. PMID: 37341641.

Gonzalez-Lugo JD, Kambhampati S, Yacoub A, Donnellan WB, Berdeja J, Bhagat P, Fehn K, Remy C, Jasra S, Kazemi M, Pradhan K, Kim M, Mantzaris I, Sica RA, Shah N, Goldfinger M, Kornblum N, Gritsman K, Braunschweig I, Steidl U, Will B, Shastri A, Verma A. Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial. Clin Cancer Res. 2023 Jan 4;29(1):60-66. doi: 10.1158/1078-0432.CCR-22-1457. PMID: 36255372.

Potts KS, Cameron RC, Metidji A, Ghazale N, Wallace L, Leal-Cervantes AI, Palumbo R, Barajas JM, Gupta V, Aluri S, Pradhan K, Myers JA, McKinstry M, Bai X, Choudhary GS, Shastri A, Verma A, Obeng EA, Bowman TV.Cell Rep. 2022 Dec. Splicing factor deficits render hematopoietic stem and progenitor cells sensitive to STAT3 inhibition.PMID: 36516770

Okoye-Okafor UC, Javarappa KK, Tsallos D, Saad J, Yang D, Zhang C, Benard L, Thiruthuvanathan VJ, Cole S, Ruiz S, Tatiparthy M, Choudhary G, DeFronzo S, Bartholdy BA, Pallaud C, Ramos PM, Shastri A, Verma A, Heckman CA, Will B.J Exp Med. 2022 Nov 7. Megakaryopoiesis impairment through acute innate immune signaling activation by azacytidine. PMID: 36053753

Adrianzen-Herrera D, Sparks AD, Shastri A, Zakai NA, Littenberg B. Geographic disparities in cardiovascular mortality among patients with myelodysplastic syndromes: A population-based analysis. Cancer Epidemiol. 2022 Oct. PMID : 35970010

Jasra S, Giricz O, Zeig-Owens R, Pradhan K, Goldfarb DG, Barreto-Galvez A, Silver AJ, Chen J, Sahu S, Gordon-Mitchell S, Choudhary GS, Aluri S, Bhagat TD, Shastri A, Bejan CA, Stockton SS, Spaulding TP, Thiruthuvanathan V, Goto H, Gerhardt J, Haider SH, Veerappan A, Bartenstein M, Nwankwo G, Landgren O, Weiden MD, Lekostaj J, Bender R, Fletcher F, Greenberger L, Ebert BL, Steidl U, Will B, Nolan A, Madireddy A, Savona MR, Prezant DJ, Verma A. High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster. Nat Med 2022 Mar;28. PMID: 35256801

Shastri A, Adrianzen-Herrera DA. Ruxolitinib in CMML: A Case Study of Innovative Trial Design in a Rare Cancer. Clin Cancer Res. 2021 Nov. PMID : 34531297

Chakraborty S, Shapiro LC, de Oliveira S, Rivera-Pena B, Verma A, Shastri A. Therapeutic targeting of the inflammasome in myeloid malignancies. Blood Cancer J. 2021 Sep 14. PMID: 34521810

Lugo-Gonzalez J, Chakraborty S, Verma A, Shastri A. The Evolution of Epigenetic Therapy in Myelodysplastic Syndromes & Acute Myeloid Leukemia. Seminars in Hematology. Dec 2020. PMID : 33509444

Kaur G, Mejia Saldarriaga M, Shah N, Catamero DD, Yue L, Ashai N, Goradia N, Heisler J, Xiao Z, Ghalib N, Aaron T, Cole D, Foreman R, Mantzaris I, Derman O, Bachier L, Sica RA, Kornblum N, Braunschweig I, Shastri A, Goel S, Verma A, Janakiram M. Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data. Clin Lymphoma Myeloma Leuk. 2020 Nov 21. PMID: 33339770

Shastri A, Lugo-Gonzalez J, Verma A. Understanding FLT3 Inhibitor Resistance to Rationalize Combinatorial AML Therapies. Blood Cancer Discov. 2020 Dec. PMID :34661152

Adrianzen Herrera D, Pradhan K, Snyder R, Karanth S, Janakiram M, Mantzaris I, Braunschweig I, Budhathoki A, Shah UA, Verma AK, Murthy SB, Shastri A. Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis. Leucemia. 2019 Dec 16. PMID : 31844145

Sridharan A, Schinke CD, Georgiev G, Da Silva Ferreira M, Thiruthuvanathan V, MacArthur I, Bhagat TD, Choudhary GS, Aluri S, Chen J, Pradhan K, Xia Y, Panjikaran M, Sims G, Bhagat CK, Bender R, Keeler L, Graber A, Heuck C, Fletcher FA, Alapat D, Weinhold N, Johnson SK, Wickrema A, Barlogie B, Morgan GJ, Shastri A, Steidl U, Will B, Verma A. Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood Advances. 2019 Dec 10; PMID : 31805192

Kaner JD, Thibaud S, Jasra S, Wang Y, Janakiram M, Sharma A, Sridharan A, Elias H, Polineni R, Assal A, Weiss L, Braunschweig I, Steidl U, Pradhan K, Shastri A, Chaitowitz M, Zingman B, Will B, Mantzaris I, Verma A. HIV portends a poor prognosis in myelodysplastic syndromes. Leukemia Lymphoma. 2019 Dec. PMID : 3128224

Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, Bhattacharyya S, Lopez R, Pradhan K, Giricz O, Ravipati G, Wong L, Cole S, Bhagat T, Feld J, Dhar Y, Bartenstein M, Thiruthuvanathan V, Wickrema A, Ye H, Frank D, Pellagatti A, Boultwood J, Zhou T, Kim Y, MacLeod R,Epling-Burnette PK, Ye M, McCoon P, Woessner R, Steidl U, Will B and Verma A. Antisense STAT3 Inhibitor Decreases Viability of Myelodysplastic and Leukemic Stem Cells. Journal of Clinical Investigation, Dec 2018, PMID : 30252677

Kao YR, Chen J, Narayanagari SR, Todorova TI, Aivalioti MM, Ferreira M, Ramos PM, Pallaud C, Mantzaris I, Shastri A, Bussel JB, Verma A, Steidl U, Will B. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag. Science Translational Medicine. Sept 2018. PMID : 30209246

Snyder R, Libby T, Raciti P, Amin B, Jacobson M, Rakheja D, Fleming K, Bartenstein M, Zhu C, Goel S, Verma AK, Shastri A. Myelodysplastic Syndrome and Sweets Syndrome Are Associated with a Mutation in Isocitrate Dehydrogenase 1. Anticancer Research. April 2018, PMID : 29599340

Shastri A; Verma A; Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML. Lancet Haematology. Jan 2018, PMID : 29241763

Kanna S; Choudhary G; Ramachandran N; Steidl U; Verma AK; Shastri A. STAT3 inhibition as a therapeutic strategy for leukemia. Leuk Lymphoma. 2017 Nov 22. PMID : 29164994

Darbinyan K*; Shastri, A*; Budhathoki, A*; Helbig, D; Pradhan K et all. Hispanic Ethnicity is Associated with Younger Age at Presentation and Worse Survival in Acute Myeloid Leukemia. Blood Advances. * Equally Contributed 2017 Oct. PMID: 29296859

Shastri A; Mantaris I; Yu Y; Janakiram M; Verma A; Barta SK. Sites of Extranodal Invovlement Are Prognostic I n Patients with Stage 1 Follicular Lymphoma: An Analysis of the Surveillance, Epidemiology and End Results Database. Oncotarget. 2017 Jul 14. PMID: 29108238

Shastri A; Budhathoki A; Barta S; Kornblum N; Derman O; Battini R; Raghupathy R; Verma A; Frenette P; Braunschweig I; Janakiram M. Stimulation of Adrenergic Activity by Desipramine Enhances Hematopoietic Stem and Progenitor Cell Mobilization along with G-CSF in Multiple Myeloma. Am J Hematol. 2017 Jul 4. PMID: 28675459

Shastri A; Will B; Steidl U; Verma A. Stem Cell Alterations In Myelodysplastic Syndromes. Sangre, 2017 Feb, PMID: 28159737

Schinke, C, Giricz O, Li W, Shastri A, Gordon S, Barreyro L, Bhagat T, Bhattacharya S, Will B, Steidl U, Verma A. IL-8/CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells,
Blood, 2015 Mar, PMID: 25810490

Shastri A, Shastri SS. Cancer screening and prevention in low-resource environments.
Nature Reviews Cancer, 2014 Dec; PMID: 25355377

Daver N,* Shastri A,* Kadia T, Quintas-Cardama A, Pemmaraju N, Jabbour E, Konopleva M, O’Brien S, Pierce S, Cortes J, Kantarjan H, Verstovsek S. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
Leukemia Research 2014 Jul, PMID: 25047979 * Equally Contributed

Publicaciones

Impact of race and ethnicity on early mortality in multiple myeloma: a SEER analysis

Improving Unrelated Donor Equity: Assessing Mismatched Donor Opportunities with Real-World Data in a Minority-Predominant Cohort

Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency

Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study

A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis

Atypical chronic myeloid leukemia (CML) with ETV6-ABL1 mutation managed successfully with a third-generation TKI and hematopoietic stem cell transplant

Inter-racial genetic differences in myelofibrosis: a diverse inner-city center analysis

Mechanisms of resistance to hypomethylating agents and BCL-2 inhibitors

Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review

Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients with Cancer and COVID-19

Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma

Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents

A Co-Management Model for Myeloid Malignancies That Evolved during the COVID-19 Pandemic

Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation

A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML

Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis

Role of IL8 in myeloid malignancies

Splicing factor deficits render hematopoietic stem and progenitor cells sensitive to STAT3 inhibition

Correction: Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer (Journal of Hematology &amp; Oncology, (2022), 15, 1, (70), 10.1186/s13045-022-01286-4)

Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer

Megakaryopoiesis impairment through acute innate immune signaling activation by azacitidine

Unrelated Allogeneic Stem Cell Transplant in Relapsed/Refractory AML: Widening the Yellow Brick Road

ABCL-038 HIV Status Affects Access to Autologous Stem Cell Transplant in Primary Central Nervous System B-Cell Lymphomas in a Minority Rich, Ethnically Diverse and Socioeconomically Disadvantaged Population at Montefiore Medical Center/Albert Einstein College of Medicine

ABCL-161 Reasons for Non-Referral for Autologous Stem Cell Transplantation in Central Nervous System Lymphoma (CNSL) Patients in a Minority-Rich, Multiracial, and Underprivileged Population at Montefiore Medical Center, Albert Einstein College of Medicine

AML-351 Low-Dose Weekly Decitabine and Venetoclax in TP53-Mutated Myeloid Malignancies

Geographic disparities in cardiovascular mortality among patients with myelodysplastic syndromes: A population-based analysis.

TCL-150 Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma

Autologous stem cell transplantation in an older adult population

Efficacy and safety of CAR-T cell therapy in minorities

Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster

Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations

High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination

Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort

Ruxolitinib in CMML: A case study of innovative trial design in a rare cancer

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine

Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world setting

Therapeutic targeting of the inflammasome in myeloid malignancies

Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population

Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data

Understanding FLT3 Inhibitor Resistance to Rationalize Combinatorial AML Therapies

The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia

The thrombopoietin mimetic JNJ-26366821 increases megakaryopoiesis without affecting malignant myeloid proliferation

A case series of Monoclonal Gammopathy of Undetermined Significance and COVID-19

Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis

Epidemiology and survival trend of adult T-cell leukemia/lymphoma in the United States

Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis

Correction: Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer (Journal of Hematology & Oncology, (2022), 15, 1, (70), 10.1186/s13045-022-01286-4)